Neurana Leadership

Who is Neurana Pharmaceuticals

Meet the leadership team

David Hale

Chairman, President and CEO

Mr. Hale serves as Chairman, President and CEO of Neurana Pharmaceuticals. He is Chairman and CEO of Hale BioPharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. He was involved in the formation and development of SkinMedica, an aesthetic skincare company, and served as Executive Chairman and Chairman through the sale of the Company to Allergan in 2012. Mr. Hale served as Chairman of Santarus, Inc. prior to its sale to Salix Pharmaceuticals in 2014, Micromet prior to its sale to Amgen in 2012, Somaxon Pharmaceuticals prior to its sale to Pernix in 2013, and Crisi Medical Systems, Inc. prior to its sale to Becton Dickinson & Co. in 2015.


Mr. Hale is a serial entrepreneur who has been involved in the formation and/or development of a number of life sciences companies. In addition to the companies above, these include Hybritech, Viagene, Gensia Sicor, CancerVax, Neurelis, MDRejuvena, Dermata, Adigica Health, Oncternal, Clarify Medical, Agility Clinical and Biocept. He serves on the board of two public companies, Conatus and Biocept.

Judy Caron, PhD

Chief Operating Officer & Head of Clinical Development

A co-founder of Neurana, Dr. Caron joined the company in 2015 as the Chief Operating Officer and Vice President of Clinical Development. Her responsibilities include Project Management, Clinical Development, Chemistry and Pharmaceutical Development, and Regulatory Operations. Dr. Caron has over 25 years of experience in pharmaceutical development. She began her career at Sandoz Pharmaceuticals where she managed projects in the therapeutic areas of oncology and immunology. In 1997, she joined Sepracor Inc., a research-based pharmaceutical company focused on the development and commercialization of products in the field of CNS and respiratory disease, as Vice President of CNS Drug Development. At Sepracor, Dr. Caron directed several CNS projects, including the development and approval of Lunesta® in the US and Japan, where Lunesta® became the first CNS drug to be approved via a bridging strategy. In 2008, Dr. Caron became COO and a partner at BioNevia Pharmaceuticals, LLC, a biotech focused on diabetic treatments. Dr. Caron holds a PhD in molecular genetics.

Kathy Scott

Chief Financial Officer

Ms. Scott is the Chief Financial Officer of Neurana Pharmaceuticals and a Venture Partner at Hale BioPharma Ventures.  Ms. Scott is also the Chief Financial Officer for some of Hale BioPharma Ventures’ portfolio companies, including Adigica Health and Recros Medica.  Ms. Scott was previously the CFO of Clarify Medical, MDRejuvena, Oncternal Therapeutics, BioSurplus and FeRx. 


Previously Ms. Scott was a Partner at RA Capital Advisors, a San Diego private investment bank providing financial advisory services. She spent over 15 years with RA Capital Advisors, completing billions of dollars of mergers, acquisitions, divestitures, and restructurings for a broad range of corporate clients.  Ms. Scott started her career as an auditor in Arthur Andersen’s San Diego office, focusing on both public and private clients. She is a CPA and CFA charter holder.